DeepQure Appoints Jason G. Jones to Lead Clinical and Regulatory Affairs

DeepQure Enhances Clinical Leadership

DeepQure, a trailblazer in the field of hypertension treatment, revealed a significant update with the appointment of Jason G. Jones as the Global Vice President of Clinical Regulatory Affairs. This strategic hire comes at a pivotal moment as the company aims to consolidate its position as a leader in the development of next-generation therapies for hypertension.

Jason Jones, who previously held a senior leadership role at SoniVie, a company noted for its innovative intravascular ultrasound renal denervation treatment, is expected to be a driving force behind DeepQure’s clinical initiatives. His tenure at SoniVie not only saw the company successfully complete its Early Feasibility Study but also led to a notable acquisition by Boston Scientific for $540 million earlier this year.

With over 20 years of experience in clinical and regulatory affairs, Jones has a proven track record in managing complex clinical trials and navigating various regulatory environments. His arrival at DeepQure is seen as a game-changer, potentially accelerating the company’s global clinical trial efforts and advancing its HyperQure™ product line.

In an official statement, Jones expressed enthusiasm for the innovative technology at DeepQure. He stated, “I was truly captivated by DeepQure's unique technology and its tremendous potential.” HyperQure™ is designed as a minimally invasive extravascular renal denervation system targeting resistant hypertension and related cardiovascular conditions. The device represents a novel approach by performing circumferential ablation of nerves surrounding the renal artery, thereby enhancing the effectiveness and durability of treatment solutions.

DeepQure's leadership anticipates that Jones’s extensive expertise will provide the necessary momentum to drive the company’s global clinical ambitions. A spokesperson emphasized, “Jason's wealth of experience and proven leadership will be a game-changer as DeepQure establishes itself as a global leader in next-generation hypertension therapies.”

Founded by experts from diverse fields, DeepQure is committed to revolutionizing treatment methodologies for hypertension and related disorders. Headquartered in Seoul, South Korea, it has clinical trial programs facilitating innovation for patients both in Korea and the United States. With Jason at its helm, the company is setting the stage for a transformative shift in how hypertension is managed worldwide.

In conclusion, the combination of Jason G. Jones’s experience and DeepQure’s pioneering technologies may foster advancements in cardiology and public health, driving comprehensive solutions for patients suffering from hypertension.

As the landscape of hypertension treatment continues to evolve, DeepQure's strategic appointments and powerful innovations may well shape the future of this critical area of healthcare, aiming to meet the growing needs of patients effectively.